Pharming Group Exceeds 2025 Revenue Guidance, Announces Investor Day for Pipeline and 2026 Outlook

summarizeSummary

Pharming Group N.V. reported preliminary 2025 revenues of approximately $376 million, surpassing its upwardly revised guidance, and announced a virtual Investor Day on February 3, 2026, to discuss pipeline advancements and 2026 financial guidance.

check_boxKey Events

• Preliminary 2025 Revenue Exceeds Guidance

  Pharming Group reported preliminary, unaudited 2025 revenues of approximately $376 million, surpassing its upwardly revised guidance range of $365 million to $375 million.

• Strong Commercial Growth

  The company achieved approximately 27% revenue growth in 2025 compared to 2024, driven by continued demand for RUCONEST® and increased patient uptake for Joenja® in the U.S. and internationally.

• Operating Expenses Within Range

  Full-year 2025 operating expenses are expected to be within the previously communicated range of $304 million to $308 million, demonstrating cost discipline.

• Investor Day Announcement

  Pharming will host a virtual Investor Day on February 3, 2026, to provide a comprehensive update on its advancing clinical pipeline, including leniolisib and KL1333, and to present its 2026 financial guidance.

auto_awesomeAnalysis

Pharming Group's preliminary 2025 revenue exceeding its previously raised guidance signals strong commercial performance, particularly for RUCONEST® and Joenja®. This positive momentum, coupled with disciplined operating expenses, provides a solid foundation for 2026. The upcoming Investor Day is a key event for investors, as it will offer a comprehensive update on the company's clinical pipeline, including leniolisib and KL1333, and provide crucial 2026 financial guidance. This event will be critical for understanding the company's future growth drivers and strategic direction.